# Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

> **NCT00914459** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 37 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** Moroctocog alfa ( AF-CC)
- **PROCEDURE:** Laboratory tests

## Key facts

- **NCT ID:** NCT00914459
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2016-03
- **Final completion:** 2016-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00914459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00914459, "Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00914459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*